Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients
The DOI matches its Crossref record; 50 of the 51 references it cites were found in a registry or an index.
Abstract
The serotonin transporter gene promoter polymorphism (5-HTTLPR) has been repeatedly associated with antidepressant response in mood disorder patients, but findings are not consistent across studies. A meta-analysis was performed on 15 studies including data of 1435 subjects. We tested three phenotypes: remission rate, response rate and response rate within 4 weeks using the cochrane review manager. We observed a significant association of the s/s variant of 5-HTTLPR with remission rate (P<0.0001) and both s/s and s/l variants with response rate (P=0.0002). Response rate within 4 weeks was associated in both models (P=0.003-P<0.00001). This effect is quite robust to ethnic differences although a significant heterogeneity is present in Asian samples.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“L-alleles result in greater mRNA transcription and more active 5-HTT function (Parsey et al., 2006) and have been associated with a better treatment response to selective serotonin reuptake inhibitor (SSRI) antidepressants although discrepant findings exist (Serretti et al., 2007).”
From Affective Cognition and its Disruption in Mood Disorders (2011) · cites this paper as Serretti et al., 2007
Citations
Cites
Allelic Variation of Human Serotonin Transporter Gene Expression
Heils, A., Teufel, A., Petri, S., Stöber, G., Riederer, P., Bengel, D., & Lesch, K. P. (1996) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1996.66062621.x · Cited by 2,221
Size and burden of mental disorders in Europe—a critical review and appraisal of 27 studies
Wittchen, H.-U., & Jacobi, F. (2005) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2005.04.012 · Cited by 1,503
Diagnosis and definition of treatment-resistant depression
Fava, M. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00231-2 · Cited by 1,380
Hu, X.-Z., Lipsky, R. H., Zhu, G., Akhtar, L. A., Taubman, J., Greenberg, B. D., Xu, K., Arnold, P. D., Richter, M. A., Kennedy, J. L., et al. (2006) · The American Journal of Human Genetics · doi:10.1086/503850 · Cited by 1,123
(1994) · PharmacoResources · doi:10.1007/bf03289581 · Cited by 974
DEFINITION AND EPIDEMIOLOGY OF TREATMENT-RESISTANT DEPRESSION
Fava, M., & Davidson, K. G. (1996) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(05)70283-5 · Cited by 797
Kirchheiner, J., Nickchen, K., Bauer, M., Wong, M.-L., Licinio, J., Roots, I., & Brockmöller, J. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001494 · Cited by 724
Meta-analysis of genetic association studies
Munafò, M. R., & Flint, J. (2004) · Trends in Genetics · doi:10.1016/j.tig.2004.06.014 · Cited by 642
The human serotonin transporter gene linked polymorphism (5-HTTLPR) shows ten novel allelic variants
Nakamura, M., Ueno, S., Sano, A., & Tanabe, H. (2000) · Molecular Psychiatry · doi:10.1038/sj.mp.4000698 · Cited by 633
Smeraldi, E., Zanardi, R., Benedetti, F., Bella, D. D., Perez, J., & Catalano, M. (1998) · Molecular Psychiatry · doi:10.1038/sj.mp.4000425 · Cited by 614
Cited by
Items 201–300 of 535
Kato, M., Zanardi, R., Rossini, D., Ronchi, D. D., Okugawa, G., Kinoshita, T., Colombo, C., & Serretti, A. (2009) · Psychiatry Research · doi:10.1016/j.psychres.2007.12.012 · Cited by 34
Self-citationTowards the clinical implementation of pharmacogenetics in bipolar disorder
Salloum, N. C., McCarthy, M. J., Leckband, S. G., & Kelsoe, J. R. (2014) · BMC Medicine · doi:10.1186/1741-7015-12-90 · Cited by 34
“Fifteen studies encompassing 1,435 MDD and BD patients were analyzed for association with SSRI response [94].”
MethodSantangelo, A. M., Ito, M., Shiba, Y., Clarke, H. F., Schut, E. H. S., Cockcroft, G. J., Ferguson‐Smith, A. C., & Roberts, A. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2016.41 · Cited by 34
Ma, Y., Wang, C., Luo, S., Li, B., Wager, T. D., Zhang, W., Rao, Y., & Han, S. (2016) · NeuroImage · doi:10.1016/j.neuroimage.2016.04.064 · Cited by 32
“…processes of pain, for example, pain-related unpleasantness is associated with activity in the MCC, AI and cerebellum (Rainville et al., 1997; Singer et al., 2004; Craig, 2011; Bushnell et al., 2013) whereas activity increases in the thalamus reflect a general arousal reaction to pain…”
BackgroundPharmacogenetic analysis of opioid dependence treatment dose and dropout rate
Crist, R. C., Li, J., Doyle, G. A. R., Gilbert, A. P. W., DeChairo, B. M., & Berrettini, W. H. (2018) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990.2017.1420795 · Cited by 32
“less benefit from SSRIs than other patients (36,37).”
BackgroundLenze, E. J., Goate, A., Nowotny, P., Dixon, D. J., Shi, P., Bies, R. R., Lotrich, F. K., Rollman, B. L., Shear, M. K., Thompson, P. A., et al. (2010) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181fc2bef · Cited by 32
“We also recoded genotype based on S versus L genotype alone, in line with previous research.(6) The analyses showed similar results: those with the S/S genotype (n = 25) had an escitalopram versus placebo cumulative response rate of 76% versus 70% (P = 0.”
BackgroundResultKato, M., Wakeno, M., Okugawa, G., Fukuda, T., Azuma, J., Kinoshita, T., & Serretti, A. (2007) · Neuropsychobiology · doi:10.1159/000119734 · Cited by 31
Self-citationGanea, K., Menke, A., Schmidt, M. V., Lucae, S., Rammes, G., Liebl, C., Harbich, D., Sterlemann, V, Storch, C., Uhr, M., et al. (2012) · Translational Psychiatry · doi:10.1038/tp.2012.104 · Cited by 31
Hoirisch-Clapauch, S., Nardi, A. E., Gris, J., & Brenner, B. (2014) · Thrombosis Research · doi:10.1016/j.thromres.2014.02.028 · Cited by 34
“A recent meta-analysis [15] showed an association between the 5HTTLPR long allele and increased response to SSRIs, and their reduced side effects.”
BackgroundMajor Depressive Disorder: New Clinical, Neurobiological, and Treatment Perspectives
Kupfer, D. J., Frank, E., & Phillips, M. L. (2016) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.140208 · Cited by 33
Kato, M., Okugawa, G., Wakeno, M., Takekita, Y., Nonen, S., Tetsuo, S., Nishida, K., Azuma, J., Kinoshita, T., & Serretti, A. (2009) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2009.06.006 · Cited by 33
“Additionallywe included 5-HTTLPR gene as covariate in analysis in a genotype wise way (s/s=0, s/l=1, l/l=2) thus implying codominance, as we observed it to be associated with SSRIs response in this as well as another sample and meta-analysis (Kato et al., 2006; Serretti et al., 2007).”
ResultSelf-citationSreeja, V., Jose, A., Patel, S., Menon, B., Athira, K. V., & Chakravarty, S. (2023) · Neurochemistry International · doi:10.1016/j.neuint.2023.105672 · Cited by 35
Ming, Q., Zhang, Y., Yi, J., Wang, X., Zhu, X., & Yao, S. (2015) · BMC Psychiatry · doi:10.1186/s12888-015-0639-y · Cited by 31
“Meta-analyses have demonstrated the different effects of 5-HTTLPR on selective serotonin reuptake inhibitors (SSRIs) efficacy between Caucasians and Asians [35, 36].”
BackgroundPsychotropic prescription practices in east Asia: looking back and peering ahead
Tan, C., Shinfuku, N., & Sim, K. (2008) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e32830e6dc4 · Cited by 32
Kato, M., Wakeno, M., Okugawa, G., Fukuda, T., Takekita, Y., Hosoi, Y., Azuma, J., Kinoshita, T., & Serretti, A. (2008) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2008.01.019 · Cited by 34
“Furthermore, no significant association could be observed with intolerance to SSRIs in the whole subjects.”
BackgroundSelf-citationPharmacogenetics and the serotonin transporter in late-life depression
Gerretsen, P., & Pollock, B. G. (2008) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425250802560279 · Cited by 32
“heterogeneity exists in Asian samples [27] .”
BackgroundInfluentialIs 5-HTTLPR linked to the response of selective serotonin reuptake inhibitors in MDD?
Illi, A., Poutanen, O., Setälä-Soikkeli, E., Kampman, O., Viikki, M., Huhtala, H., Mononen, N., Haraldsson, S., Koivisto, P. A., Leinonen, E. V. J., et al. (2010) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-010-0126-x · Cited by 30
“[21] also confirmed this, and the authors concluded that this effect is quite robust in spite of a significant heterogeneity is present in Asian samples.”
ResultMajor Depressive Disorder: New Clinical, Neurobiological, and Treatment Perspectives
Kupfer, D. J., Frank, E., & Phillips, M. L. (2014) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.12.2.217 · Cited by 30
Efficacy of Exercise in Reducing Depressive Symptoms across 5-HTTLPR Genotypes
Rethorst, C. D., Landers, D. M., Nagoshi, C. T., & Ross, J. T. D. (2010) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0b013e3181de7d51 · Cited by 33
“The effect of exercise on depressive symptoms across 5-HTTLPR genotypes is similar to the effect of SSRI, in which the ss genotype has been associated with a blunted response (39).”
BackgroundSurrogate markers of treatment outcome in major depressive disorder
Papakostas, G. I. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711001246 · Cited by 28
“…and treatment outcome in MDD, with a number of pooled meta-analyses confirming a by guest on June 8, 2016 http://ijnp.oxfordjournals.org/ D ow nloaded from predictive role, more so for Caucasian than Asian patients (Kato & Serretti, 2010 ; Serretti et al. 2006, 2007 ; Smits et al. 2004).”
BackgroundOverview of pharmacogenomic testing in clinical practice
Gross, T., & Daniel, J. (2018) · Mental Health Clinician · doi:10.9740/mhc.2018.09.235 · Cited by 29
“Patients with non-Hispanic, white ancestry demonstrated this benefit, and patients with Asian ancestry were less likely to show the same amount of benefit.(11) There also appears to be no difference in escitalopram efficacy with SLC6A4 polymorphisms in the Indian population.”
BackgroundNielsen, D. A., Harding, M. J., Hamon, S., Huang, W., & Kosten, T. R. (2012) · Genes Brain & Behavior · doi:10.1111/j.1601-183x.2012.00839.x · Cited by 29
Kurose, K., Hiratsuka, K., Ishiwata, K., Nishikawa, J., Nonen, S., Azuma, J., Kato, M., Wakeno, M., Okugawa, G., Kinoshita, T., et al. (2012) · Psychiatry Research · doi:10.1016/j.psychres.2012.01.023 · Cited by 30
Self-citationYoshimura, R., Umene‐Nakano, W., Suzuki, A., Ueda, N., Miyamoto, K., Ikenouchi, A., Hori, H., Otani, K., & Nakamura, J. (2009) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.1043 · Cited by 28
“E-mail: yoshi621@med.uoeh-u.ac.jp Copyright # 2009 John Wiley & Sons, Ltd. the long allele genotypes (L/L and L/S) showed a greater response to SSRIs than those with the short allele genotype (S/S) (Smits et al., 2004; Serretti et al., 2007).”
BackgroundInfluentialThe serotonin transporter gene and effectiveness of SSRIs
Serretti, A., & Kato, M. (2007) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.8.1.111 · Cited by 29
Self-citationFunctional Characterization of Liver Enhancers That Regulate Drug-Associated Transporters
Kim, M., Skewes-Cox, P., Fukushima, H., Hesselson, S., Yee, S. W., Ramsey, L. B., Nguyen, L., Eshragh, J. L., Castro, R. A., Wen, C. C., et al. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.353 · Cited by 27
The intersection of pharmacology, imaging, and genetics in the development of personalized medicine
Gerretsen, P., Müller, D. J., Tiwari, A. K., Mamo, D. C., & Pollock, B. G. (2009) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2009.11.4/pgerretsen · Cited by 35
“heterogeneity exists in Asian samples.(62) In contrast to Caucasian subjects, Asians carrying the S allele have been reported to respond better to antidepressants, although findings are mixed (see refs 37, 58, 63).”
Rentzsch, J., Adli, M., Wiethoff, K., de Castro, A. G.-C., & Gallinat, J. (2013) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-013-0424-1 · Cited by 29
Phillips, J. L., Batten, L. A., Tremblay, P., Aldosary, F., Du, L., & Blier, P. (2015) · Acta Neuropsychiatrica · doi:10.1017/neu.2015.25 · Cited by 29
Pharmacogenomic Implications of Variants of Monoaminergic-Related Genes in Geriatric Psychiatry
Shiroma, P. R., Geda, Y. E., & Mrazek, D. A. (2010) · Pharmacogenomics · doi:10.2217/pgs.10.118 · Cited by 26
The Pharmacogenetics of Major Depression: Past, Present, and Future
Laje, G., & McMahon, F. J. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.09.016 · Cited by 27
Mitchell, N. C., Gould, G. G., Koek, W., & Daws, L. C. (2016) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.116.233338 · Cited by 27
“Another population that is reported to show a limited therapeutic response to SSRIs is comprised of individuals carrying low-expressing SERT gene variants (Serretti et al., 2007).”
BackgroundDada, R., Tolahunase, M., & Sagar, R. (2018) · Indian Journal of Psychiatry · doi:10.4103/psychiatry.indianjpsychiatry_398_17 · Cited by 29
Altered inflammatory responsiveness in serotonin transporter mutant rats
Macchi, F., Homberg, J. R., Calabrese, F., Zecchillo, C., Racagni, G., Riva, M. A., & Molteni, R. (2013) · Journal of Neuroinflammation · doi:10.1186/1742-2094-10-116 · Cited by 25
“Furthermore, considering that depressed patients with higher levels of cytokines, as well as individuals carrying the S variant of the 5-HTTLPR polymorphism, are less responsive to antidepressant treatment [53,54], we may speculate that alterations of the immune/inflammatory system in depressed individuals may not onl…”
BackgroundDepression and Coronary Heart Disease: More Pieces of the Puzzle
Carney, R. M., & Freedland, K. E. (2007) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.07071053 · Cited by 29
“This response to SSRIs in patients with the S allele has been well documented in older adults (11), but a recent meta-analysis of available studies concluded that there is a highly significant association of the S variant of the 5-HTTLPR with remission and response rates across all ages (13).”
BackgroundPsychiatric comorbidities of migraine
(2024) · Handbook of Clinical Neurology · doi:10.1016/b978-0-12-823357-3.00013-6 · Cited by 25
Dombrovski, A. Y., Mulsant, B. H., Ferrell, R. E., Lotrich, F. E., Rosen, J., Wallace, M. J., Houck, P. R., Mazumdar, S., & Pollock, B. G. (2009) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e328333ee10 · Cited by 27
“Caucasian patients with depression, the low-expression S allele has been associated with poor SSRI response, although evidence in other ethnic groups is less consistent (Serretti et al., 2007).”
ResultRotberg, B., Kronenberg, S., Carmel, M., Frisch, A., Brent, D. A., Zalsman, G., Apter, A., & Weizman, A. (2013) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2012.0020 · Cited by 26
“…the connection between 5-HTTLPR gene polymorphism and the response to SSRIs demonstrated a favorable response among Caucasian patients carrying the long allele of the 5-HTTLPR gene in contrast to patients carrying the short allele (Weizman et al. 2000; Serretti et al. 2007, Porcelli et al. 2012).”
Pharmacogenetics of antidepressive treatment
Zobel, A. W., & Maier, W. (2010) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-009-0091-4 · Cited by 26
“[49] as it was published more recently.”
BackgroundInfluentialEllerbrock, I., Sandström, A., Tour, J., Fanton, S., Kadetoff, D., Schalling, M., Jensen, K. B., Sitnikov, R., & Kosek, E. (2021) · Molecular Brain · doi:10.1186/s13041-021-00789-4 · Cited by 25
Gattuso, J. J., Wilson, C., Hannan, A. J., & Renoir, T. (2023) · Journal of Neurochemistry · doi:10.1111/jnc.16017 · Cited by 28
“Thus, this KO model may be relevant to clinical populations of GAD and MDD that do not respond to SSRI treatments (Serretti et al., 2007).”
Shiroma, P. R., Drews, M. S., Geske, J. R., & Mrazek, D. A. (2013) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2013.02.012 · Cited by 24
Maciukiewicz, M., Marshe, V. S., Tiwari, A. K., Fonseka, T. M., Freeman, N., Rotzinger, S., Foster, J. A., Kennedy, J. L., Kennedy, S. H., & Müller, D. J. (2015) · Pharmacogenomics · doi:10.2217/pgs.15.136 · Cited by 26
Serotonin Transporter Gene Polymorphism Associated with Short-Term Treatment Response to Venlafaxine
Lee, S., Choi, T.-K., Lee, E. M., Seok, J., Lee, S. H., Lee, H. S., & Kim, S. J. (2010) · Neuropsychobiology · doi:10.1159/000319362 · Cited by 26
Incomplete Coverage of Candidate Genes: A Poorly Considered Bias
Serretti, A., Drago, A., & Ronchi, D. D. (2007) · Current Genomics · doi:10.2174/138920207783591681 · Cited by 24
“[35] 1435 (meta”
Self-citationAllelic variation in 5-HTTLPR and the effects of citalopram on the emotional neural network
Ma, Y., Li, B., Wang, C., Zhang, W., Rao, Y., & Han, S. (2015) · British Journal of Psychiatry · doi:10.1192/bjp.bp.114.150128 · Cited by 23
Kato, M., Serretti, A., Nonen, S., Takekita, Y., Wakeno, M., Azuma, J., & Kinoshita, T. (2015) · Translational Psychiatry · doi:10.1038/tp.2015.6 · Cited by 25
Self-citationSeripa, D., Pilotto, A., Paroni, G., Fontana, A., D’Onofrio, G., Gravina, C., Urbano, M., Cascavilla, L., Paris, F., Panza, F., et al. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115578159 · Cited by 24
“Our genetic findings are similar to the observation by Kim et al. (2006) in the Korean population, despite probable differences in nature for the distinctly Asian genetic background (Serretti et al., 2007).”
BackgroundResultvan Roekel, E., Masselink, M., Vrijen, C., Heininga, V. E., Bak, T., Nederhof, E., & Oldehinkel, A. J. (2016) · BMC Psychiatry · doi:10.1186/s12888-016-0880-z · Cited by 24
“Finally, previous research has shown that genes involved in the dopaminergic system, notably COMT and DAT [38, 39], as well as the BDNF gene [40] are related to reward processing, and that individuals with certain genetic variants in the DRD4 [41] and the SCL6A4 [42] gene are more susceptible for treatment.”
Valderrama, J., & Miranda, R. (2017) · Psychiatry Research · doi:10.1016/j.psychres.2017.08.092 · Cited by 25
“Indeed, 5-HTTLPR genotype and allele frequencies differ across ethnic populations (Kunugi et al., 1997; Serretti et al., 2007).”
Pharmacogenetics of SSRIs and Sexual Dysfunction
Osis, L., & Bishop, J. R. (2010) · Pharmaceuticals · doi:10.3390/ph3123614 · Cited by 26
“those with an LL genotype) prior to treatment may exhibit an increase in signaling at these postsynaptic receptors, which is consistent with data suggesting that these patients have a greater clinical improvement to SSRI therapy [40].”
ResultDepression and the cardiovascular system: increasing evidence of a link and therapeutic implications
Marano, G., Harnic, D., Lotrionte, M., Biondi‐Zoccai, G., Abbate, A., Romagnoli, E., & Mazza, M. (2009) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.09.78 · Cited by 25
Neuroimaging genomic studies in major depressive disorder: A systematic review
Zhang, H., Mellor, D. J., & Peng, D. (2018) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12829 · Cited by 24
Won, E., Chang, H.-S., Lee, H.-Y., Ham, B., & Lee, M.-S. (2012) · Neuropsychobiology · doi:10.1159/000341876 · Cited by 23
Drugs, genes and the blues: Pharmacogenetics of the antidepressant response from mouse to man
O’Leary, O. F., O'Brien, F. E., O’Connor, R. M., & Cryan, J. F. (2013) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2013.10.015 · Cited by 22
Smith, T., Sharp, S., Manzardo, A. M., & Butler, M. G. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms16034416 · Cited by 21
“Possession of two S variants is associated with a poor or slow response to SSRIs or with adverse events [10,15].”
BackgroundOuthred, T., Das, P., Dobson‐Stone, C., Felmingham, K. L., Bryant, R. A., Nathan, P. J., Malhi, G. S., & Kemp, A. H. (2016) · Journal of Affective Disorders · doi:10.1016/j.jad.2016.02.019 · Cited by 22
“Previous research has shown that, in comparison to ‘L’ allele carriers, ‘S/S’ homozygotes display lower remission and response rates when treated with SSRIs (Kato and Serretti, 2010; Licinio and Wong, 2011; Serretti et al., 2007).”
BackgroundResultInfluentialPharmacogenetics of Selective Serotonin Reuptake Inhibitors in Pediatric Depression and Anxiety
Kronenberg, S., Frisch, A., Rotberg, B., Carmel, M., Apter, A., & Weizman, A. (2008) · Pharmacogenomics · doi:10.2217/14622416.9.11.1725 · Cited by 26
SERT and NET polymorphisms, temperament and antidepressant response
Andre, K., Kampman, O., Illi, A., Viikki, M., Setälä-Soikkeli, E., Mononen, N., Lehtimäki, T. J., Haraldsson, S., Koivisto, P. A., & Leinonen, E. V. J. (2015) · Nordic Journal of Psychiatry · doi:10.3109/08039488.2015.1012554 · Cited by 23
Genetic Prediction of Antidepressant Drug Response and Nonresponse in Korean Patients
Lim, S., Won, H., Kim, H. R., Myung, W., Kim, S., Kim, K.-K., Carroll, B. J., Kim, J., & Kim, D. K. (2014) · PLoS ONE · doi:10.1371/journal.pone.0107098 · Cited by 20
TAAR 6 and HSP-70 variations associated with bipolar disorder
Pae, C., Drago, A., Mandelli, L., Ronchi, D. D., & Serretti, A. (2009) · Neuroscience Letters · doi:10.1016/j.neulet.2009.09.025 · Cited by 20
Self-citationThe Promise and Reality of Pharmacogenetics in Psychiatry
Zandi, P. P., & Judy, J. (2010) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2010.07.004 · Cited by 26
Lekman, M., Paddock, S., & McMahon, F. J. (2008) · Molecular Diagnosis & Therapy · doi:10.1007/bf03256297 · Cited by 22
“[86] In sum, previous literature suggests that the S/S genotype may be associated with risk of depression and reduced response to SSRI treatment.”
BackgroundAvailability of the serotonin transporter in patients with alcohol dependence
Ho, P., Shih, M.-C., Ma, K., Huang, W.-S., Ho, K. K.-J., Yen, C.-H., Lu, R., & Huang, S. (2010) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2010.503813 · Cited by 20
“The frequencies of S allele are 42% in “ Caucasians ” and 79% in “ Asians ” , and the signifi cant difference in 5-HTT allelic constitution may lead to heterogeneity (Serretti et al. 2007).”
BackgroundJonassaint, C. R., Ashley‐Koch, A. E., Whitfield, K. E., Hoyle, R. H., Richman, L. S., Siegler, I. C., Royal, C. D. M., & Williams, R. B. (2012) · Biological Psychology · doi:10.1016/j.biopsycho.2012.05.004 · Cited by 24
Hodgson, K., Mufti, S., Uher, R., & McGuffin, P. (2012) · Genome Medicine · doi:10.1186/gm351 · Cited by 20
Muhonen, L. H., Lahti, J. M. T., Alho, H., Lönnqvist, J. K., Haukka, J. K., & Saarikoski, S. T. (2010) · Psychiatry Research · doi:10.1016/j.psychres.2010.07.039 · Cited by 19
“Sincecontradictoryobservationshavebeenmadebetween5-HTTLPR and depression (Kraft et al., 2007; Serretti et al., 2007) we used the comorbidity of alcohol dependence, which is also linked to serotonergic neurotransmission, in order to obtain greater homogeneity in the depression phenotype used in this study.”
MethodSahraian, S., Babashams, M., Rezasoltani, P., Najmabadi, H., Kahrizi, K., & Gorgani, S. H. (2013) · PubMed Central · Cited by 21
Empirically supported psychological treatments and the Research Domain Criteria (RDoC)
McKay, D., & Tolin, D. F. (2016) · Journal of Affective Disorders · doi:10.1016/j.jad.2016.10.018 · Cited by 20
Lett, T. A. P., Walter, H., & Brandl, E. J. (2016) · CNS Drugs · doi:10.1007/s40263-016-0385-9 · Cited by 21
“2) [25] in contrast to its association with amygdala activation with a comparatively larger effect size (Cohen’s d *0.”
BackgroundPharmacogenetics and Psychoactive Drug Therapy: Ready for the Patient?
Steimer, W. (2010) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e3181e1a78d · Cited by 19
“75 in a meta-analysis with 750 patients.(45) This has recently been confirmed in 795 escitalopram-treated patients.”
BackgroundAre some adolescents differentially susceptible to the influence of bullying on depression?
Iyer, P. A., Dougall, A. L., & Jensen‐Campbell, L. A. (2013) · Journal of Research in Personality · doi:10.1016/j.jrp.2013.02.004 · Cited by 19
Sprague-Dawley and Fischer Female Rats Differ in Acute Effects of Fluoxetine on Sexual Behavior
Miryala, C. S. J., Hiegel, C., & Uphouse, L. L. (2012) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2012.02981.x · Cited by 19
Roiser, J. P., Levy, J., Fromm, S. J., Goldman, D., Hodgkinson, C. A., Hasler, G., Sahakian, B. J., & Drevets, W. C. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112442789 · Cited by 18
“Second, there have been several reports that carriers of the high-expression 5-HTTLPR allele are more responsive to antidepressant medication (Kato and Serretti, 2010; Serretti et al., 2007), although again this pharmacogenetic interaction has received inconsistent support (Taylor et al.”
BackgroundResultInfluentialMice lacking the serotonin transporter do not respond to the behavioural effects of psilocybin
Gattuso, J. J., Wilson, C., Li, S., Hannan, A. J., & Renoir, T. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177304 · Cited by 18
Influence of 5-HTTLPR polymorphism on resting state perfusion in patients with major depression
Brockmann, H., Zobel, A. W., Schuhmacher, A., Daamen, M., Joe, A., Biermann, K., Schwab, S. G., Biersack, H., Maier, W., & Boecker, H. (2010) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2010.08.016 · Cited by 18
Variation of 5-HTTLPR and deficits in emotion regulation: A pathway to risk?
Gilman, T. L., Latsko, M. S., Matt, L. M., Flynn, J. J., Cabrera, O. D. L. C., Douglas, D. G., Jasnow, A. M., & Coifman, K. G. (2015) · Psychology & Neuroscience · doi:10.1037/pne0000017 · Cited by 19
“Larger sample sizes would also strengthen the power to evaluate heterozygous (LS=) individuals separately from homozygous S=S= and LL groups instead of grouping the former with one of the latter, as we have done here and is frequently done in the literature (Serretti et al., 2007).”
BackgroundResultLauriola, M., Mangiacotti, A., D’Onofrio, G., Cascavilla, L., Paris, F., Ciccone, F., Greco, M., Paroni, G., Seripa, D., & Greco, A. (2018) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000492489 · Cited by 21
van Dalfsen, J. H., & Markus, C. R. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.05.047 · Cited by 20
Pharmacogenetic Study of Serotonin Transporter and 5HT2A Genotypes in Autism
Najjar, F., Owley, T. B., Mosconi, M. W., Jacob, S., Hur, K., Guter, S. J., Sweeney, J. A., Gibbons, R. D., Cook, E. H., & Bishop, J. R. (2015) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2014.0158 · Cited by 19
“The serotonin transporter gene (SLC6A4) and the serotonin receptor 2A gene (HTR2A) have both been implicated in treatment response to and tolerability of SSRIs, although these relationships have primarily been examined in adults (McMahon et al. 2006; Serretti et al. 2007).”
Ye, R., Carneiro, A. M. D., Airey, D., Sanders‐Bush, E., Williams, R. W., Lu, L., Wang, J., Zhang, B., & Blakely, R. (2013) · Genes Brain & Behavior · doi:10.1111/gbb.12092 · Cited by 17
“…variation in the 5-HT transporter (SERT) promoter (5HTTLPR) has been associated with neuroticism (Lesch et al. 1996), the impact of early life stress on mood disorder risk (Caspi et al. 2003; Karg et al. 2011) and in SSRI response (Arias et al. 2003; Pollock et al. 2000; Serretti et al. 2007).”
BackgroundSalem, A. M., Kamel, I., Rashed, L. A., & Din, S. F. G. (2016) · International Journal of Impotence Research · doi:10.1038/ijir.2016.36 · Cited by 17
Ethnopsychopharmacology and Pharmacogenomics
Hernán Silva, I. (2013) · Advances in psychosomatic medicine · doi:10.1159/000348741 · Cited by 19
Tomita, T., Yasui‐Furukori, N., Nakagami, T., Tsuchimine, S., Ishioka, M., Kaneda, A., Sugawara, N., & Kaneko, S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0098099 · Cited by 17
“Previous studies have reported that the S allele was associated with worse response [44,45], higher remission [46], lower tolerability, and more frequent side effects of MDD treatments [47].”
BackgroundThe Pharmacogenetics of Depression: Enter the GWAS
Malhotra, A. K. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.10020244 · Cited by 17
Outhred, T., Das, P., Dobson‐Stone, C., Felmingham, K. L., Bryant, R. A., Nathan, P. J., Malhi, G. S., & Kemp, A. H. (2014) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867414533837 · Cited by 19
“…a potential explanation for the manner in which the ‘L’ alleles are able to predict improved response to and remission with antidepressant treatment (Kato and Serretti, Australian & New Zealand Journal of Psychiatry, 48(12) 2010; Licinio and Wong, 2011; Ruhé et al., 2009; Serretti et al., 2007).”
BackgroundResultInfluentialAntidepressants and Adolescent Brain Development
Karanges, E. A., & McGregor, I. S. (2011) · Future Neurology · doi:10.2217/fnl.11.51 · Cited by 18
“Studies have shown that the short (s) form of this variable-length repeat region is less transcriptionally active than the long (l) form, and has been associated with increased risk of major depressive disorder and other psychiatric diagnoses [179], poorer antidepressant response [180], and greater propensity to devel…”
BackgroundPharmacogenetics: a reality or misplaced optimism?
Mutsatsa, S., & Currid, T. (2012) · Journal of Psychiatric and Mental Health Nursing · doi:10.1111/j.1365-2850.2012.01910.x · Cited by 16
“Recently, two meta-analyses of pharmacogenetic studies of antidepressants have reported associations between some serotonin gene variants and treatment response (Serretti et al. 2007).”
BackgroundSaito, Y. A., Locke, R. G., Almazar, A. E., Bouras, E. P., Howden, C. W., Lacy, B. E., DiBaise, J. K., Prather, C. M., Abraham, B. P., El‐Serag, H. B., et al. (2017) · The American Journal of Gastroenterology · doi:10.1038/ajg.2017.52 · Cited by 17
Fuying, Z., Yingying, Y., Shining, Z., Kezhong, Z., Shi, Y., Xuemei, Z., Yin, C., Jinxia, C., Li, H., Wu, Y., et al. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.05.023 · Cited by 17
AL-Eitan, L. N., Jaradat, S. A., Qin, W., Wildenauer, D. M. B., Wildenauer, D., Hulse, G. K., & Tay, G. K. (2012) · Toxicology and Industrial Health · doi:10.1177/0748233712462446 · Cited by 16
“A meta-analysis of 1400 subjects of different ethnicities from 15 studies reported reduced response to antidepressant therapy in ‘S’ allele carriers (Serretti et al., 2006).”
Pharmacogenetics of neurological and psychiatric diseases at older age: has the time come?
Lozupone, M., Panza, F., Stella, E., Montagna, M. L., Bisceglia, P., Miscio, G., Galizia, I., Daniele, A., Mauro, L. D., Bellomo, A., et al. (2016) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2017.1246533 · Cited by 17
“major depressive disorders (MDDs) and resistance to treatment [103,117].”
BackgroundInfluentialJarčušková, D., Tkáč, I., Hlaváčová, N., Yaluri, A. S., Kozárová, M., Habalová, V., Klimčáková, L., Židzik, J., Javorský, M., & Bednářová, A. (2024) · BMC Psychiatry · doi:10.1186/s12888-024-06162-8 · Cited by 18
“Carriers of the S allele, particularly those homozygous for the S variant (S/S) have been found to have lower remission rates and poorer responses to SSRI [16].”
BackgroundDrago, A., & Serretti, A. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3182189c64 · Cited by 16
“66 at the sixth month of treatment(12)) and comparable to the genetic effect.(13) In conclusion, we found that the impact of the sociodemographic variables in response to treatment does not change if environmental conditions in which patients are treated are different.”
BackgroundSelf-citationRahikainen, A., Majaharju, S., Haukka, J. K., Palo, J. U., & Sajantila, A. (2017) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.32553 · Cited by 15
Novel Antidepressant-Like Properties of the Iron Chelator Deferiprone in a Mouse Model of Depression
Uzungil, V., Tran, H., Aitken, C. M., Wilson, C., Opazo, C., Li, S., Payet, J. M., Mawal, C., Bush, A. I., Hale, M. W., et al. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01257-0 · Cited by 16
“A further utility of the 5-HTT KO mice is that it can be considered as a model of antidepressant treatment resistance, as both individuals who carry the s allele of the 5-HTTLPR and the 5-HTT KO mouse have reduced response to selective serotonin reuptake inhibitors [18, 23, 24].”
BackgroundHuang, E., Hettige, N. C., Zai, G. C., Tomasi, J., Huang, J., Zai, C. C. H., Pivac, N., Perković, M. N., Tiwari, A. K., & Kennedy, J. L. (2018) · The Pharmacogenomics Journal · doi:10.1038/s41397-018-0041-5 · Cited by 17
Wells, J. L., Brown, C. L., Hua, A. Y., Soyster, P. D., Chen, K., Dokuru, D. R., Coppola, G., Haase, C. M., & LEVENSON, R. W. (2019) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2019.04.009 · Cited by 16
Imaging genetics: implications for research on variable antidepressant drug response
Rabl, U., Scharinger, C., Müller, M., & Pezawas, L. (2010) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.10.35 · Cited by 17
Mandal, T., Bairy, L. K., & Sharma, P. S. V. N. (2020) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-020-02866-4 · Cited by 14
Metadata
- Authors
- Serretti, A., Kato, M., De Ronchi, D., & Kinoshita, T.
- Affiliations
- University of Bologna (IT)
- Kansai Medical University (JP)
- Corresponding author
- Serretti, A
- Venue
- Molecular Psychiatry
- Published
- 2006-12-05
- Volume
- 12
- Issue
- 3
- Pages
- 247-257
- ISSN
- 1359-4184 (ISSN-L)
- 1476-5578
- OpenAlex
- W1982886582
- Cited by
- 529
- References
- 51
- Citations by year
- 2026: 4 · 2025: 4 · 2024: 9 · 2023: 13 · 2022: 12 · 2021: 44 · 2020: 10 · 2019: 18 · 2018: 22 · 2017: 23 · 2016: 28 · 2015: 29 · 2014: 23 · 2013: 38 · 2012: 39
- FWCI
- 3.78
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Molecular Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- 5-HTTLPR, serotonin transporter gene, promoter polymorphism, selective serotonin reuptake inhibitors, antidepressant response, depression, remission rate, genetic association, ethnic differences, Asian populations
- MeSH terms
- Adult, Aged, Depressive Disorder, Female, Humans, Male, Middle Aged, Polymorphism, Genetic, Promoter Regions, Genetic, MEDLINE, Selective Serotonin Reuptake Inhibitors, Serotonin Plasma Membrane Transport Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.